Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov;25(6):859-65.
doi: 10.1097/EDE.0000000000000157.

Use of selective serotonin-reuptake inhibitors during pregnancy and the risk of clubfoot

Mahsa M Yazdy  1 , Allen A Mitchell, Carol Louik, Martha M Werler
Affiliations

Use of selective serotonin-reuptake inhibitors during pregnancy and the risk of clubfoot

Mahsa M Yazdy et al. Epidemiology. 2014 Nov.

Abstract

Background: Selective serotonin-reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants. Previous studies have suggested that SSRIs may increase the risk of birth defects, including clubfoot. Using data from a population-based case-control study, we evaluated whether SSRI use increased the risk of clubfoot.

Methods: Mothers were interviewed within 1 year after delivery about sociodemographic factors, pregnancy events, and exposures. They were specifically asked if they experienced depression or anxiety or if they took any of the following SSRIs: citalopram, escitalopram, fluvoxamine, paroxetine, sertraline, or fluoxetine. We used logistic regression models to calculate odds ratios (ORs) and 95% confidence intervals (CIs).

Results: We included a total of 622 clubfoot cases and 2002 nonmalformed controls born between 2006 and 2011 in Massachusetts, New York, and North Carolina. For the 2nd or 3rd lunar month of pregnancy (the relevant gestational period), SSRI use for a period of more than 30 days was higher in case mothers (5%) than control mothers (3%). After adjustment for maternal smoking and body mass index, the OR for any SSRI use and clubfoot was 1.8 (95% CI = 1.1-2.8). When individual SSRIs were examined, ORs were elevated for sertraline (1.6 [0.8-3.2]), paroxetine (9.2 [0.7-484.6]), and escitalopram (2.9 [1.1-7.2]).

Conclusion: Our data suggest an increased risk of clubfoot occurrence in relation to SSRI use. Drug-specific risks varied widely, and some estimates were unstable.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: MMW holds consultancy contracts with Amgen, Abbott, and UCB; no financial relationships with any organizations that might have an interest in this work; and no other relationships or activities that could appear to have influenced these analyses. AAM and CL received GlaxoSmithKline support for an analysis of bupropion in relation to cardiac defects. AAM serves as a member of advisory committees for Biogen-Idec’s pregnancy registries for biologics used to treat multiple sclerosis. MMY states no known conflicts of interest.

Figures

Figure 1
Figure 1
Frequency of selective serotonin reuptake inhibitor use among control mothers, Massachusetts, New York, and North Carolina, 2006 – 2011. The denominator for each lunar month includes only control mothers who were pregnant in that lunar month
Figure 2
Figure 2
Frequency of selective serotonin reuptake inhibitor use in the 2nd and 3rd lunar months among control mothers by year of last menstrual period, Massachusetts, New York, and North Carolina, 2006 – 2011.
See this image and copyright information in PMC

Comment in

  • In utero SSRI exposure and risk of clubfoot.
    Henriksen DP, Pottegård A, Jimenez-Solem E, Damkier P. Henriksen DP, et al. Epidemiology. 2015 May;26(3):e34-5. doi: 10.1097/EDE.0000000000000276. Epidemiology. 2015. PMID: 25835138 No abstract available.
  • The authors respond.
    Yazdy MM, Mitchell AA, Louik C, Werler MM. Yazdy MM, et al. Epidemiology. 2015 May;26(3):e35-6. doi: 10.1097/EDE.0000000000000281. Epidemiology. 2015. PMID: 25835139 Free PMC article. No abstract available.

References

    1. Alwan S, Reefhuis J, Rasmussen SA, Friedman JM, Study NBDP Patterns of Antidepressant Medication Use Among Pregnant Women in a United States Population. The Journal of Clinical Pharmacology. 2011;51(2):264–270. - PubMed
    1. Cooper WO, Willy ME, Pont SJ, Ray WA. Increasing use of antidepressants in pregnancy. American Journal of Obstetrics and Gynecology. 2007;196(6):544. e1–544. e5. - PubMed
    1. Wichman CL, Fothergill A, Moore KM, Lang TR, Heise RH, Jr, Watson WJ. Recent trends in selective serotonin reuptake inhibitor use in pregnancy. Journal of Clinical Psychopharmacology. 2008;28(6):714–716. - PubMed
    1. Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. New England Journal of Medicine. 2007;356(26):2675–2683. - PubMed
    1. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ: British Medical Journal. 2009;339 - PMC - PubMed

Publication types

Substances